DaVita Inc. (DVA) Earnings Call Transcript & Summary
August 1, 2022
Earnings Call Speaker Segments
Joel Ackerman
executiveThanks for joining us on this second quarter conference call, and welcome. We’re grateful that you continue to take an interest in our company. This is Joel Ackerman, CFO and Treasurer, and with me today is Javier Rodriguez, our CEO. I’d like to point out that on this call we might make forward-looking statements as that term is defined under the federal securities laws. Each of those statements carries known and unknown risks and uncertainties, which could lead actual results to differ materially from what the forward-looking statements describe. If you want more information about those risks and uncertainties, please see our second quarter earnings press release along with our SEC filings, which include our latest annual report on Form 10-K, every later quarterly report on Form 10-Q, and other filings we subsequently make with the SEC. Our forward-looking statements rest on information available to us at present, and we have no intention, and assume no obligation, to update them, except where the law requires it. In addition, we want to remind you that some non-GAAP financial measures will be discussed on this call. A reconciliation of those non-GAAP measures to the most comparable GAAP financial measures appears in our earnings press release furnished to the SEC and posted on our website. I’ll now hand the call over to Javier Rodriguez.
Javier Rodriguez
executiveThanks for that, Joel, and it's good that everybody was able to join the call. There are five topics I plan to cover today: health equity and the Supreme Court case, our results for the second quarter, an update on how Integrated Kidney Care, or IKC, is doing, and finally I'll close with our current thinking regarding 2023. Before I get into business matters, though, I want to start with a clinical topic that carries tremendous importance for society: health equity. Since kidney disease strikes patients of color with such disproportionate severity, there may be no more important goal than achieving health equity. On the dimensions that count the most — access to care, access to information, and clinical outcomes — DaVita and the kidney care community have achieved equity that is unmatched relative to the vast majority of other disease states; we've drawn on the reach our scale gives us to provide care and education that are both uniform and just. The outcomes and protocols we lead the field on have reduced variation across every patient population, regardless of race or socioeconomic status. When you examine dialysis adequacy, phosphorus, and calcium lab values, as well as hospitalizations and mortality, our black and Hispanic patients are at parity. As one further example of how we advance health equity, our Kidney SMART program is now available in 10 languages, and we're participating in a pilot focused on developing culturally tailored education for patient communities that are underrepresented and underserved. On access, most patients are able to obtain dialysis services within 10 miles of their homes; these results make us proud, and we've now set our sights on making transplant and home dialysis easier to reach; so, turning to SCOTUS, the ruling in the Marietta Memorial Hospital case opened a loophole that allows plans to circumvent the long-standing protections our patients enjoy under the Medicare Secondary Payer Act, or MSPA. It remains our position that this narrow interpretation not only contradicts Congress's intent when it enacted these provisions, but could also harm this vulnerable patient group and reverse health equity gains. Together with the community, we're advancing several initiatives meant not only to close this loophole but also to invoke other anti-discrimination provisions so these patients can retain their right to choose whichever insurance option fits them best. The first step in that effort is supporting the legislative work of members of Congress who care deeply about protecting dialysis patient rights as well as the Medicare trust fund. We were excited that last Friday, bipartisan legislation arrived that would allow Congress to do exactly that by amending the MSPA's text to close the loophole the Marietta decision opened. Under the proposed legislation, it's made clear that a benefit plan seeking to limit or impair benefits based on the need for renal dialysis services — the Marietta plan, for instance — would count as a violation of the MSPA. Passing any bill during an election year is going to be an uphill fight. Still, we view bringing back the MSPA as something that won't stir controversy, and we'll partner with the Congressional Budget Office to ensure it's scored as a saver, which should smooth the path to approval. We're likewise working with regulators so that substitute anti-discrimination protections might be applied to the discrimination practiced through the Marietta Memorial Hospital employee group. The proposed revisions to the Affordable Care Act's anti-discrimination provisions released last week demonstrate that HHS is serious about protecting individuals from insurance benefit designs that discriminate for many reasons, including disability. Should employer groups start attempting to modify benefit plans in order to take advantage of the MSPA loophole created by the Marietta decision, litigation may ensue under those anti-discrimination protections. Let's now shift to the financials. Operating income for Q2 reached 433 million, alongside earnings per share of $2.30. Compared with the prior quarter, operating income increased by 95 million, Q1's seasonal impacts diminished, and treatments per day grew about 1% over the previous quarter. Among our patients, COVID infections and deaths declined following the Q1 Omicron surge through May, before climbing in June and again in July. Treatment rates similarly fell sharply from Q1's highs, but remained above normal seasonal levels during Q2; the way COVID influences mortality mid-treatment and treatment volumes remains difficult to forecast and represents the biggest swing factor for our performance in the latter half of 2022 and heading into 2023. Labor costs continued to be a headwind in Q2, with heavier reliance on contracted labor and base wage increases similar to what we experienced in Q1. We're restraining other patient care costs and G&A to partially offset wage and other inflationary pressures. Notwithstanding these headwinds, we still expect our results to fall within the lower half of our 2022 guidance range of 1.525 billion to 1.675 billion. Turning to an update on our IKC business. Operating losses in our IKT business came in better than expected during Q2. That resulted from timing across 2022, since we recognized certain shared savings revenue earlier than planned; we also benefited from favorable prior period development in our special need plan; for the full year, we anticipate IKC's overall performance will surpass our original projections. Looking ahead, our confidence in our care model keeps growing because of early results from our 2021 Share Saving Trust; for 2023, we also expect substantially stronger growth in membership and dollars under management across both <<inaudible>> and CKCD <<inaudible>> programs. Owing to the stronger 2022 performance and the first-year costs associated with substantial growth, we now expect the improvement in IKC operating income for 2023 to land below our earlier projections. Lastly, I'd like to provide an update on how we're approaching 2023 overall. To help our investors and analysts with these updates. Looking at the outlook section of the press release, you'll find a table showing the key drivers we expect to affect operating income growth from 2022 into 2023. We still believe a significant rebound is coming next year, though challenges and uncertainty around treatment volume growth and the healthcare labor market have led us to reduce the improvement range to 200 million to 300 million. Let me walk you through how our thinking has shifted. First, back in November of 2021, we thought the volume headwinds from COVID would be over by 2023, and we expected benefits from a pull forward of COVID-related mortality. Those factors would have driven above-normal volume growth in the middle of our range, plus a volume tailwind in 2023 compared to our historical results. Based on what we've seen from the winter Omicron surge and how the pandemic has continued to evolve, we now expect COVID will remain a headwind to growth in 2023. Uncertainty around intensive treatment volume growth is still the largest single driver of variability in our year-over-year profit forecasts. Second, our confidence has increased in both the likelihood and the scale of the cost saving initiatives we've been working on. We have plans in place to reduce procurement costs, or our fixed cost structure, and to shrink G&A. Some non-recurring expenses in 2022 and 2023 will result from this, but over the long term it should lower our cost structure. Third, relative to what we knew at Capital Markets Day, we now expect higher revenue per treatment growth next year. This is driven by higher rate increases and lower patient bad debt. To sum up for 2023, we still expect a meaningful increase of 200 million to 300 million, but because of volume and wage pressure, we are lowering that range. I'll now hand it over to Joel to go through our financial performance and outlook in more detail, including the $1.675 billion figure.
Joel Ackerman
executiveAppreciate that, Javier. To kick things off, I want to provide a bit more color around our Q2 performance. Compared with the first quarter, U.S. dialysis treatments rose 2.3%. Two factors drove that: one extra treatment day, plus roughly a 1% gain in treatments per day. As the initial Omicron wave faded, excess mortality dropped considerably from Q1. I should flag that this tailwind seems to have flipped in June and July, with a fresh surge weighing on volumes. Mistreatment rates came down during the quarter, following the usual seasonal pattern, yet they stayed elevated versus normal for Q2 owing to the new Omicron subvariants. Quarter-over-quarter, revenue per treatment climbed by $4.19. The main drivers were the customary seasonal uptick from patients hitting their coinsurance and deductibles, plus the ongoing migration to MA plans — partly countered by a seasonal dip in acute treatment volume and the partial expiration of Medicare sequestration relief during Q2. On a quarter-over-quarter basis, patient care costs per treatment fell by $5.47, largely from the seasonal nature of health benefits, payroll taxes, and reduced costs in several other areas. Versus Q1, G&A rose by roughly $24 million. During Q2, contributions to the industry's effort against the California ballot initiative totaled about $23 million. That represents a pull forward of spending originally slated for Q3. Our full-year estimates for the ballot initiative spend remain unchanged, though the timing between Q2 and Q3 does shift. On top of that, we booked a one-time gain of $22 million from selling certain self-developed properties, which roughly canceled out the pulled-forward ballot initiative spend. The quarter-over-quarter G&A increase mostly came from higher compensation expense and greater T&E. To tie it all together and help you frame Q2 as a baseline for the remainder of the year, a few points are worth highlighting. First, the ballot initiative expense during the quarter was offset by the gain on self-developed property sales. Both flow through the G&A line, and together they had no material effect on the quarter. Second, IKC results for the quarter came in well above expectations for two reasons. First, we recorded roughly $15 million of shared savings revenue that had been anticipated in the latter half of 2022. Second, we saw positive prior period development of about $10 million. Combined, those produced roughly $25 million of benefit in the quarter that we don't expect to repeat in the back half of 2022. Beyond those components, there were other items, as there are each quarter, but they mostly netted out against each other. So what all of that adds up to is that our quarterly earnings got a lift of roughly $25 million on a net basis versus the baseline we'd apply when modeling earnings for the year's back half; when it comes to Q3 and Q4, the sole meaningful seasonal or unusual item we foresee right now is the money being spent on the California budget initiative; during Q2 we bought back about 3.9 million shares of our stock, and another 901,000 shares have been repurchased since that quarter closed. One last thing I'd like to tack onto what Javier said regarding the bridge to 2023 operating income: as he noted, we're lowering the range for the adjusted OI increase in 2023 to $200 million to $300 million. The steps we're taking to hit that range should generate non-recurring expenses in 22 and 2023; our guidance does not factor in these non-recurring costs. Operator, please open the call for Q&A.
Kevin Fischbeck
analystAlright, excellent, thank you. There are a few things I want to ask about. From what I'm hearing, you raised the guidance on pricing for the coming year — is there a way to break down what shifted there, for instance how much stems from an improved expectation for the Medicare rate adjustment as opposed to MA rates or commercial?
Joel Ackerman
executiveYes, Kevin, that really breaks into 3 pieces. The first is the Medicare rate, which you mentioned. The second involves certain operational and systems modifications we plan to implement in-house that we believe can produce greater yield, or greater cash collections, and that in the end translates into a higher RPT. The third consists of certain benefit adjustments that will affect the patient portion and better our bad debt, since the smaller the patient portion becomes in connection with out-of-pocket costs, the more that declines, the more we will end up collecting. This has nothing to do with any assumption on our part about elevated rates in commercial or MA.
Kevin Fischbeck
analystAll right. I guess the question is whether there's any downside view here — clearly, with that Marietta situation you just mentioned, plus the steps the industry is taking to address it — but I suppose, is there some expectation, or any early signal, regarding the way commercial contracts are getting worked out?
Javier Rodriguez
executiveKevin, this is Javier. The brief response is that it's too soon to say. So we keep monitoring it, and should we observe anything, we'll tell you. Like we mentioned previously, one segment is more probable than not to be affected — namely that small employer — yet matters of this kind require time. Therefore, there's nothing fresh for us to share on that front.
Kevin Fischbeck
analystAll right. And then I suppose you said there's a change relative to the outlook you originally had, a bridge for '23, you hold a different opinion regarding volumes — how much of that stems from mass compared with what has already occurred in the arithmetic of that moving ahead, compared with your altered or more cautious view concerning how matters could unfold down the road.
Joel Ackerman
executiveI believe it concerns what lies ahead more than what has occurred up to now. Volume runs somewhat beneath what we anticipated. Yet the bigger factor is our forecast for excess mortality from here, not what has already taken place.
Javier Rodriguez
executiveAs you'll recall, Kevin, we discussed a bit the idea of a pull forward — at one point we described it as a sort of COVID unwind. Our thinking was that after that excess mortality worked its way out, we'd see somewhat stronger growth in a single year, and at this point we simply lack visibility. Of course, mathematically it's going to occur, but when it occurs is not something we can see. So that's the math Joel just mentioned.
Kevin Fischbeck
analystAlright, so the overall operating income figure hasn't moved. It's simply that the timing is too hard to forecast. Which means you're removing a portion of it for the coming year.
Joel Ackerman
executiveActually, the total OI for 2023 has moved — it's been reduced by 75 at the midpoint of the range. Previously it stood at $250 million to $400 million. Now we've shifted that to 200 to 300. So, 75 at the midpoint, and I'd say it's reasonable to attribute all of that 75 to our revised volume expectations. There are a few other puts and takes as well.
Kevin Fischbeck
analystMy impression was that you had mentioned something along the lines of $150 million to $200 million of OI stemming from COVID normalization as it relates to volumes over time. Does that remain the correct frame of reference, or has that figure stayed the same?
Joel Ackerman
executiveRegarding volumes, I don't believe our perspective on normalization coming out of COVID has shifted. Rather than continuing to focus on what the negative OI impact from COVID looks like, we've moved toward acknowledging that where we stand now represents the new baseline, and the question becomes how we progress from this point. That said, when it comes to the pull forward, and eventually excess mortality needing to diminish and ultimately fall below normal levels, our conviction on that remains unchanged.
Kevin Fischbeck
analystGreat, thanks very much.
Justin Lake
analystThank you. I've got a pair of additional questions building on what Kevin asked. To start, you mentioned certain benefit modifications that should lower what patients pay out of their own pockets — could you shed a bit more light on that?
Joel Ackerman
executiveSure. What this involves is a shift in how Medicare determines the cap on out-of-pocket spending — and for dual eligibles especially, since that's where we feel it, our MA book contains a particularly large dual population, and with this Medicare adjustment to the maximum out-of-pocket amount, these dual-eligible members arrive at that ceiling sooner than the patient portion does — and as you're aware, we gather very little of that patient portion — so they get there earlier in the year. Consequently, what you'd call the patient bad debt figure declines, by $1.50.
Justin Lake
analystIn dollar terms for next year, what kind of effect will that have on that half of the treatment revenue?
Joel Ackerman
executiveI would put it at about a dollar and a half.
Justin Lake
analystUnderstood. And does that essentially mean the profit shows up, since that amount drops straight through to the bottom line as far as price goes?
Joel Ackerman
executiveCorrect.
Justin Lake
analystUnderstood. Now, when we consider the composition for the coming year—obviously, it’s too early to predict how employers will handle this Marietta situation. But within that updated range, have you included any expectations about payer mix getting worse? Or do you assume it remains the same?
Joel Ackerman
executiveFor 2023, we don’t anticipate any significant effect from Marietta, so the mix stays as is.
Justin Lake
analystUnderstood. Now, moving to a question about salaries and benefits — I believe the figure you'd plug in for the current year, based on your usual framework of roughly 2% to 3% raises? I think you tacked on around 75 million for this year; could you update us on where things stand relative to that extra 75 this year? And what are you building into that figure for next year? From what we figure, it seems like you might be assuming more mid-single digits once again next year? How far beyond that typical 2% to 3% are you factoring in for wage pressure next year?
Joel Ackerman
executiveYes. So Justin, just to remind you, the figure we cited was closer to 125 for this year, so let's call it a salary, wage, and benefit increase year-over-year in 22 of about 6%. And that's what we observed in the first quarter. It's what we observed in the second quarter. We anticipate that for the full year. Looking ahead to next year, we expect the figure to decline but stay well above that 2% to 3%. So roughly midway between the 3% and the 6% figure.
Justin Lake
analystAll right, that helps. Thanks for the insight.
Pito Chickering
analystHi there, good afternoon everyone, and I appreciate you fielding my questions. Returning to the IKC topic, you separated out the $50 million in shared savings along with $10 million from a prior period. Could we pull back slightly and ask what shifted in 2Q relative to what had been anticipated on Analyst Day and in your expectations? Please remind us, at this stage what is your procedure for receiving true ups from men's care planned? Also, once those true ups come in, could you share additional specifics regarding how such cost savings unfolded across '21?
Javier Rodriguez
executiveAll right, I'll have Joel address a portion of those technical items you raised. However, something I truly want us to note here is that this business carries far more volatility. Examining it from one quarter to the next is likely not an ideal approach; instead, reviewing it yearly makes more sense, given those true ups along with the unevenness and the flu's seasonal patterns and everything else that occurs within a business like this. Having said that, Joel, go ahead with the technical portion.
Joel Ackerman
executiveAbsolutely. The development from an earlier period relates to the snip business, and it looks just like the sort of prior-period development you would encounter in a managed care plan. That happens because, in our accounting there, both the entire revenue and the entire expense flow through the P&L. Regarding the $15 million of shared savings, the process obviously requires the year to close, claims to largely run their course, and data to be exchanged and reconciled. Once we feel confident that the shared savings figures are clear, that is the point at which we will recognize that revenue. So for certain 2021 plan years, we reached that confidence sooner than we had anticipated, which is what produced the $15 million of revenue in Q2 rather than in the back half of the year, where we had initially expected it. If you take a step back and look at where we stand relative to the capital market today, I'll use specific numbers just to make it clear. We had been anticipating a loss for the year from IKC of roughly $175 million. We now expect that figure to come in somewhat better, perhaps I'd say probably a $10 million to $30 million improvement compared with where we were. Part of that is prior period development, and part of it is a lower cost structure as we scale the business, where we're seeing some advantages relative to what we thought. But overall, I would stress that it is still early in the development of this business. We are expecting ups and downs, but it was a good quarter for IKC.
Pito Chickering
analystI want to dig into this a bit more. Another question — then I'll move on to a different topic. But when you consider the — the patients you had, say, in Q1 of 2021, I need your perspective on where margins stand right now, and whether these are, after 18 months or so, profitable — is there any clarity on how you go from losing money to earning money with these patients?
Joel Ackerman
executiveYes. So to start, let's be clear, we aren't earning money; we simply had positive prior period development and positive savings, and there's still an enormous expense base against those. So to some degree it's unfolding the way we anticipated with 2021, just the timing differs somewhat within the year.
Pito Chickering
analystAll right. Let me try putting that question another way — based on the numbers you're watching right now, how much time will pass before these patients stop being a loss for you and start generating profit?
Joel Ackerman
executiveDuring Capital Markets Day, we presented a roadmap in which the operation ought to reach the breakeven point around 2025, give or take, as the year when we expect we'll cross over — and nothing regarding how we see the route toward IKC profitability has shifted at this point.
Pito Chickering
analystAll right. Turning to expenses, I have a few follow-up <<inaudible>> items. What's the level of difficulty when it comes to bringing on staff right now? And how do current attrition levels compare with net additions? So how are things shaping up as the year goes on, and might a shortage of personnel create strain on treatment growth during the latter half of the year?
Javier Rodriguez
executiveI'll take that one; describing the whole nation as one uniform picture is tough, since we have sub-markets and the labor markets differ greatly from one market to the next. What I can say is it seems we've gotten past the toughest stretch, with this quarter feeling much less challenging than the prior quarter, though that prior quarter was the most difficult one the company has ever faced. So putting it in context, the labor market remains a hard one. On your second point, are there places where patients aren't being taken in? Nearly all of our clinics are taking in patients, nearly all. We do have a handful of spots, roughly 5 markets, that account for most of the ones under strain; so the way to think about it is that for a patient, the initial priority is naturally to leave the hospital. There's a great deal of anxiety tied to adjusting to your new life on dialysis. Even so, what matters most is that you want to be safe, and once staffing is right, you then save time away from home at the proper spot. At present we have an above-normal number of centers where someone must go farther than they'd like, yet they are being placed, so we're navigating those situations and expect to return to normal as the year unfolds.
Pito Chickering
analystExcellent; and I have three fast questions about figures. What does your home penetration stand at right now? How ought we to consider both interests and costs across the latter half of the year, plus the tax rate? Many thanks.
Javier Rodriguez
executiveThank you. Regarding home penetration, we saw rather flat expansion because of every one of the COVID dynamics. Consequently, that mix remains around 15%, and when it comes to the interest expense. Joel?
Joel Ackerman
executiveCorrect. When it comes to interest expense, our expectation is an increase across Q3 and Q4. Three separate factors are at play here. First, the balance outstanding on our revolver sits above what we'd consider typical. Second, LIBOR keeps climbing, and although caps apply to the majority of our floating rate debt, some of it remains uncapped. Third, since our leverage level exceeds 3.5, we move into another tier for that floating rate debt, meaning we now pay 175 over LIBOR instead of the 150 over LIBOR spread. Taking all of that into account, roughly $100 million per quarter in interest expense for Q3 and Q4 seems like a sensible estimate.
Pito Chickering
analystAnd regarding the tax rate, I suppose, what's the way we ought to consider the tax rate across the latter six months?
Joel Ackerman
executiveOn the tax rate, what I would say is our full-year guidance remains unchanged, so it holds at 25 to 27.
Pito Chickering
analystRight. Thanks so much.
Javier Rodriguez
executiveThank you, Pito.
Sarah James
analystThanks. I wanted to ask whether you folks have put additional consideration into broadening the KPIs, so we get visibility into the commercial mix — separating items such as price against volume — while recognizing certain forces at play in that area.
Javier Rodriguez
executivePardon me, Sarah — did you mention IKC? Was that your opening point? Or was there something you said at the start? I missed that part.
Sarah James
analystYeah, I was curious whether you folks are considering broadening the key performance indicators, or perhaps the metrics you share regarding commercial mix, so that pricing gets broken out separately? That way we could grasp the underlying dynamics a bit more clearly.
Javier Rodriguez
executiveSarah, my sense is that we're depending on providing commentary throughout the call, ensuring that both analysts and investors grasp which items are trending upward and which are trending downward. As for placing that into a table within the press release, that isn't something we've given thought to lately.
Sarah James
analystAll right. When it comes to partnerships, are there areas you could investigate to gain efficiency — and what about firms focused on optimized dosing as a way to reduce expenses or shipping, or really anything at all that might counterbalance the pressures we'll face over the coming several years?
Joel Ackerman
executiveAbsolutely, Sarah. Those possibilities have been on our radar for a good while, and ideally our history shows it — if you examine it on a compounded basis annually, our cost structure has risen by under 1% across that period, which demands obsessive attention, rigor, and carrying out the kinds of measures you just mentioned. Take ESA, which over the years has been our priciest drug — we've got individualized dosing along with AI-driven algorithms of the sort you brought up.
Sarah James
analystAll right. Do you have any idea how big the savings opportunity might eventually be in that particular area?
Joel Ackerman
executiveSure — it forms part of the $200 million to $300 million figure we reference for next year, so it falls within exactly that range. And on that slide, what we've included is the cost savings contained within the pharmaceutical line.
Sarah James
analystOkay. Thank you.
Joel Ackerman
executiveThank you.
Gary Taylor
analystHello, everyone, and good afternoon. I have a few questions about figures. To start, I'm circling back to the prior call—I missed the opening two or three minutes, so my apologies for that. During that call, regarding Q1, I believe you mentioned the lower half of this year's OI range. That range was restated in the release, but do you have anything further to say about the lower half for this year—is that still the case?
Joel Ackerman
executiveGary, yes, I believe we're holding to that. There's no revision regarding where within the range we expect to land.
Gary Taylor
analystAll right. And secondly, I hadn't previously been aware — obviously we have observed the proceeds from self-developed properties showing up on the cash flow statement — but I didn't know any accounting maneuvers were flowing through G&A, so thanks for flagging that this quarter. Has it ever reached this magnitude? For instance, looking back at proceeds of $56 million last year, and $93 million in 2020, I was just wondering whether any other significant gains passed through G&A?
Joel Ackerman
executiveYes. The reason it got so large this quarter is that it involved one of our central business offices, so a considerably larger building; in the past these were typically tied to clinics. So figures for individual clinics were far smaller, but — back when we were developing more clinics historically, there were more of them. So yes, you'd have seen figures similar to this; they were, I'd say, fairly consistent over time. So the reason we highlight this is that it was so large and it was anomalous compared with what you've seen lately.
Gary Taylor
analystUnderstood. The cash flow came in somewhat weaker than our expectations, and DSOs remain elevated at roughly 65. I had believed part of that tied to what you previously described, perhaps timing-related matters. Do you have any fresh perspective regarding DSO and whether, and when, it might decline?
Joel Ackerman
executiveSure, so this quarter cash taxes negatively impacted our cash flows, and that represented the major blow. Regarding DSOs, we genuinely believe an opportunity exists to reduce them. Having said that, I want to point out that our ongoing transition toward MA away from Medicare Fee-For-Service across the past 2 years will raise our DSOs by 2 days as a structural matter. Medicare pays quite rapidly, whereas MA DSOs resemble those typical of a commercial book more closely, and with Medicare Fee-For-Service shrinking while MA grows, that naturally pushes DSOs upward. Even so, I believe we can achieve a modest reduction.
Gary Taylor
analystOkay. That's my final question. I realize there are clear reasons you folks don't discuss this much in public, but regarding that <<inaudible>> contract, are we now operating on a year-to-year basis, or is it multi-year? How should we consider whether and when there might be an opportunity involving rate on ESA?
Javier Rodriguez
executiveYes. Gary, you remembered that well — our contract is set to end at the close of this year; on the ESA side, we have signed a renewed agreement, and those savings are included within the $200 million to $300 million year-over-year increase.
Gary Taylor
analystOkay. Thank you.
Javier Rodriguez
executiveThank you.
Justin Lake
analystThank you. A handful of brief follow-ups, starting with leverage. In the press release, you showed 3.8 times — could you update us on what you're targeting and where you expect that to land by the close of the year?
Joel Ackerman
executiveSure. Our goal for leverage remains unchanged, at 3 to 3.5 times, and I believe we've always stayed consistent that this is a band we aim to sit in the majority of the time, though not always. If you look back several years, you'd have observed us significantly above that band and significantly below it. Where we end up at year end and in 2023, I think, hinges on several items: share buybacks are one, clearly earnings are another, and free cash flow is a third. So we won't provide a figure, since it will hinge on each of those elements. That said, over time, we still hold the view that 3 to 3.5 times is the appropriate band for us, and we intend to return to it.
Justin Lake
analystUnderstood. Regarding share repurchases, this company has stayed remarkably steady when it comes to sending cash back to shareholders through buybacks. Do you have any views — you mentioned that leverage could potentially go even higher? Might you repurchase additional stock across the coming 6 to 18 months, rather than relying solely on free cash flow? Would you maintain that at an elevated level and tap some of that debt to retire more stock?
Joel Ackerman
executiveJustin, we remain committed to it — as you're aware, this is a complex subject — but what you can always rely on is our unwavering emphasis on giving back to shareholders; and beyond that, at the margin, the real question becomes whether you get somewhat more aggressive and take on a bit more leverage, since you believe it's a favorable opportunity, and naturally, you must also account for the fact that the world carries somewhat greater uncertainty. Right now there is a bit more uncertainty, so all of those trade-offs have to be weighed, though nothing has been ruled out.
Justin Lake
analystAll right. Then, as a final point, regarding leverage, a few questions have come my way simply because right now your debt trades at a reasonable discount to par. Do you have any views about repurchasing that debt at a discount as a way to bring leverage down, rather than doing share repurchases?
Joel Ackerman
executiveYes. What I'd say is, we examine how those two compare — in some measure, we regard both as ways to give capital back to our shareholders. So we'll evaluate each, based on where they happen to be trading. That said, I believe history makes it obvious that our preference tends toward share buybacks rather than repurchasing our debt.
Justin Lake
analystUnderstood. Then for my final question — the sector had been dealing with a scarcity of dialysis supplies during the earlier portion of this year, though I haven't really been hearing about that lately. As far as I'm aware, the expectation was for things to largely return to their usual state around June-July, so I just hoped to hear how that's going.
Javier Rodriguez
executiveRight. Appreciate it, Justin. Our stock on hand sits somewhat under its typical level, yet the stretch of intense worry, along with the need to divide things up and so on, is now finished. So my sense is that the toughest part has passed, and we're able to proceed ahead.
Justin Lake
analystAll right. Thanks again.
Javier Rodriguez
executiveThank you.
Pito Chickering
analystHi everyone, one final follow-up question here, and it's about that Medtronic deal you announced back in May. Could you give a bit more detail on the objectives, or on the transaction itself — why you felt that was the best way to use shareholder cash? Thanks.
Javier Rodriguez
executiveWell, Pito, there isn't a great deal to share. Partnering with Medtronic to develop medical innovation and technologies is something we're excited about. The one update we can give is that the FTC has cleared the Hart-Scott-Rodino waiting period, so it's a deal that promotes competition; we expected minimal scrutiny, and that's exactly what happened — naturally, the FTC could always return with questions, but this was a favorable development and, directionally, exciting for us, and it's still early. The transaction will likely close in Q1 of next year, so there's not much else to report.
Pito Chickering
analystFair enough. Thanks so much.
Javier Rodriguez
executiveThank you.
Javier Rodriguez
executiveOkay, thanks, Michelle. I’ve got just a couple of final points. To start, for more than 10 years, we have discussed how Integrated Kidney Care might help raise our patients’ quality of life while bringing overall expenses down. At this point, we have a substantial patient base, and we’re working extremely hard to put in place the systems and the capabilities required to make good on that promise. Next, as we’ve talked about, both the operating climate and the broader macro picture remain quite difficult. I feel a great deal of pride in how our teammates have shown resilience and agility, finding ways to create cost savers that help counter some of those pressures. We’re grateful for your interest in our company, and we’ll be speaking again before long. See you all.
Operator
operatorThanks. That wraps up the conference call for today. At this point, you're free to hang up.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete DaVita Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to DaVita Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DaVita Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.